TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: QR-Bromocriptine as an Adjunct to Insulin and Metformin in the Treatment of Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female patients, age 30 to 65 years of age,~2. Clinical diagnosis of type 2 diabetes at least 6 months prior to enrollment,~3. Stable on current treatment consisting of either human or recombinant multi-dose insulin therapy (MDI) with metformin,~4. HbA1c of 7.5-12%, inclusive,~5. Demonstrated willingness to check and record blood glucose readings at seven time points as instructed in the study protocol.~6. Medically controlled hypertension, at least on one anti-hypertensive~7. Medically controlled hyperlipidemia, on or off cholesterol-lowering therapy~8. BMI \>30~Exclusion Criteria:~1. Pregnancy or Lactating,~2. Type 1 Diabetes,~3. Concomitant use of forbidden medications: prescription sympathomimetics (within seven days of screening), ergot alkaloid derivatives, and anti-migraine medications,~4. Patients with history of drug or alcohol abuse within 3 years of enrollment,~5. Patients at risk for hypotension, including those who have:~   * Recent blood donation within 30 days of enrollment,~  * A history of syncopal migraines, or~  * Significant gastroparesis or orthostatic hypotension which could signify advanced autonomic neuropathy.~6. Uncontrolled mental illness especially with history of psychosis,~7. Any severe, uncontrolled or terminal medical condition which the investigator feels would interfere with the patient's ability to participate and comply with the study protocol,~8. Serum creatinine \>1.4mg/dL in females or \>1.5mg/dL in males that would preclude the patient from taking metformin,~9. LFTs elevated \>3x upper limit of normal,~10. Patients working rotating, varying or night shifts, or~11. Patient with circumstances or abnormalities (e.g. blindness or history of non-compliance) that would interfere with the interpretation of safety or efficacy data or completion of the study.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Metformin + Insulin (Type: NO_INTERVENTION): 5 patients to continue on usual type 2 diabetic treatment consisting of 70/30 insulin, metformin and exercise and nutrition counseling.
- QR-Bromocriptine +metformin+insulin (Type: EXPERIMENTAL): study drug add-on the usual therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy and Safety of Qizhiweitong Granule on Patients With Functional Dyspepsia in a Multi-center Clinical Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. patient with written ICF signed~2. patient with functional dyspepsia diagnosed by the Rome III criteria~3. age between 18y and 65y;male or female.~4. patient without gastric ulcers, erosive gastritis or other gastric organic diseases according to the endoscopy in the past one year in the hospital~5. patient without hepatobiliary and pancreatic diseases according to B-ultrasoundin the past one year in the hospital~6. patient with normal ECG (QT interval in the normal range) within one month prior to enrollment in this center~7. patient with symptoms of only one subtype of functional dyspepsia~Exclusion Criteria:~1. history of abdominal surgery;~2. take drugs related to gastrointestinal motility or gastric acid secretion and gastric acid drugs, anti-Helicobacter pylori drugs within 5 days of inclusion~3. suffering from hepatobiliary and pancreatic diseases with B ultrasound~4. suffering from high blood pressure and uncontroled hypertension~5. diabetes mellitus~6. have history of thyroid disease, systemic sclerosis, systemic lupus erythematosus~7. severe mental disorders~8. pregnant women, breastfeeding women or those who plan to become pregnant~9. allergy to Qizhiweitong particle~10. have symptoms of both subtypes of functional dyspepsia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Qizhiweitong granule (Type: EXPERIMENTAL): 2.5g/time,tid,oral administration,6 weeks
- Placebo (Type: PLACEBO_COMPARATOR): 2.5g/time,tid,oral administration,6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hospitalized for acute heart failure~* Dyspnea at rest or with minimal exertion~* Pulmonary congestion~* Able to provide informed consent~* Systolic blood pressure \> 125 mmHg~* Impaired renal function defined as an eGFR of 30-75 mL/min/1.73m2~Exclusion Criteria:~* Use of other IV therapies for acute heart failure~* Fever or sepsis~* Recent major neurologic event~* Recent major surgery~* Recent acute coronary syndrome~* Other recent investigational drug use

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): 48 hour iv infusion of placebo
- Relaxin (Type: EXPERIMENTAL): 48 hour iv infusion of relaxin at 30 ug/kg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Azithromycin in Bronchiolitis Obliterans Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Stable LTx recipients at discharge after transplantation.~* Signed informed consent~* Adult (age at least 18 years old at moment of transplantation)~* Able to take oral medication~Exclusion Criteria:~* Prolonged and/or complicated ICU-course after transplantation.~* Early (\<30 days post-transplant) post-operative death~* Major suture problems (airway stenosis or stent)~* Retransplantation (lung)~* Previous transplantation (solid organ)~* Multi-organ transplantation (lung+ other solid organ)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Azithromycin (Type: EXPERIMENTAL): 250 mg daily for 5 days, followed by 250 mg three times a week (Mon.-Wed.-Fri.) until the end of study
- Placebo (Type: PLACEBO_COMPARATOR): PLacebo daily for 5 days, followed by placebo three times a week (Mon.-Wed.-Fri.) until end of study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Effectiveness and Safety of Risperidone Compared With Placebo in the Treatment of Manic Episodes Associated With Bipolar I Disorder, and the Maintenance of Anti-manic Effectiveness of Risperidone Compared With Haloperidol

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Meets diagnosis criteria for Bipolar I Disorder - Most Recent Episode Manic (Diagnostic and Statistical Manual of Mental Diseases, 4th edition, (DSM-IV))~* meets DSM-IV criteria for a current manic episode~* hospitalized voluntarily at study initiation~* history of at least one documented manic or mixed episode prior to study initiation~* total score of \>=20 on the Young Mania Rating Scale (YMRS) and total score of \<=20 on the Montgomery Asberg Depression Rating Scale (MADRS) at start of the study~Exclusion Criteria:~* Meets DSM-IV criteria for Schizoaffective Disorder or for rapid cycling~* borderline or antisocial personality disorder~* history of substance dependence (excluding nicotine and caffeine) within the 3 months prior to study initiation~* seizure disorder~* females who are pregnant or nursing, or those lacking adequate contraception.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SNIFF 120: Study of Nasal Insulin to Fight Forgetfulness (120 Days)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 55 or greater~* Good physical health~* Memory impairment with a diagnosis of mild cognitive impairment (MCI) or Alzheimer's disease (AD)~* Participants on stable doses of Memantine (Namenda) or cholinesterase inhibitors will be eligible~Exclusion Criteria:~* Chronic sinus problems/allergies with chronic use of nasal decongestants or antihistamines~* Significant neurologic disease that might affect cognition (other than AD), such as stroke, Parkinson's disease, multiple sclerosis, severe head injury with loss of consciousness for more than 30 minutes or with permanent neurologic symptoms~* Significant medical illness or organ failure, such as uncontrolled hypertension or cardiovascular disease, chronic obstructive pulmonary disease, liver disease, or kidney disease~* Preexisting diabetes or current or previous use of hypoglycemic agents or insulin; participants will be excluded if they have a fasting blood sugar greater than 165 on baseline OGTT~* Clinically significant elevations in liver function tests, cholesterol, or triglycerides~* Major psychiatric disorders (e.g., untreated major depression and schizophrenia)~* Chronic use of the following types of medications: anti-psychotic, anxiolytic, and opiates

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): saline
- 2 (Type: EXPERIMENTAL): 10 Units
- 3 (Type: EXPERIMENTAL): 20 Units

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Deoxycholic Acid Injection Submental Fat (SMF) Magnetic Resonance Imaging (MRI) and Subject-reported Outcome Measures Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Moderate or severe submental fat~* Dissatisfaction with submental area~* History of stable body weight~* Signed informed consent~Exclusion Criteria:~* Any medical or other condition that would affect subject safety or evaluation of efficacy~* Previous intervention in the submental area

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
- Deoxycholic acid Injection 1 mg/cm² (Type: EXPERIMENTAL): Participants received deoxycholic acid 1 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
- Deoxycholic acid Injection 2 mg/cm² (Type: EXPERIMENTAL): Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-85 years,~* Admitted to the hospital because of confirmed positive SARS-CoV-2 (COVID-19 infection).~* Evidence of pulmonary involvement on CT scan or X-Ray of the chest,~* Symptom onset within the previous 10 days AND at least one additional risk factor for progression to mechanical ventilation: 1) arterial hypertension, 2) \>50 years, 3) obesity (BMI\>30.0 kg/m2), 4) history of cardiovascular disease, 5) chronic pulmonary disease, 7) chronic renal disease, 6) C-reactive protein of \>35mg/L, 7) oxygen saturation at rest in ambient air of \<94%~Exclusion Criteria:~* Contraindications to the class of drugs under study (C1 esterase inhibitor);~* History or suspicion of allergy to rabbits;~* Women who are of childbearing potential and not using methods of contraception during the entire study period;~* Pregnant or breastfeeding females or has a positive serum β-human chorionic gonadotropin (hCG) pregnancy test at screening;~* Chronic liver disease (any Child-Pugh score B or C);~* Currently admitted to an ICU or expected admission within the next 24 hours; and~* Currently receiving invasive or non-invasive ventilation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Ruconest (Type: EXPERIMENTAL): Patients receive (150 U/ml) of Ruconest at a 50 U/kg dose (max dose of 4200 U) as a slow intravenous injection via a peripheral every 12 hours; for 4 days. A total of 8 doses will be administered.
- Standard of Care (Type: OTHER): SOC

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Sero-Positive Rheumatoid Arthritis Who Are Non-Responders or Intolerant to a Single TNF-Inhibitor (PORTSMAB)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, \>/= 18 years of age~* Rheumatoid arthritis positive for rheumatoid factor and/or anti-CCP~* Non-responder or intolerant to single TNF-inhibitor therapy~* Initiating treatment with MabThera/Rituxan~Exclusion Criteria:~* Contra-indications to MabThera/Rituxan therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rituximab (Type: None): Sero-positive \[Rheumatoid Factor (RF) and/or anti-Cyclic Citrullinated Peptide (CCP+)\] rheumatoid arthritis (RA) patients, who had initiated therapy with Rituximab (MabThera) following lack of response or intolerance to a single tumour necrosis factor (TNF)-inhibitor will be included in this arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Photodynamic Therapy Alone Versus Combined With Intravitreal Bevacizumab for Age-related Macular Degeneration

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* choroidal neovascularization caused by age-related macula degeneration~* no previous treatment~* a follow-up at least 12 months~* a baseline visual acuity ranging from a letter score of 0 to 70 on the Early Treatment Diabetic Retinopathy Study chart~Exclusion Criteria:~* choroidal neovascularization caused by other eye diseases~* ocular surgery within the past 3 mouths~* history of uveitis~* intraocular pressure higher than 25 mmHg, or glaucoma~* history of systemic or ocular thromboembolic events.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bevacizumab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Effects of Oral Prednisone in Patients With Rheumatoid Arthritis (MK0000-088)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is willing to limit alcohol intake to 3 or less beverages per day~* Patient agrees to use only acetaminophen/paracetamol for breakthrough pain~Exclusion Criteria:~* Patient has other inflammatory arthritis (e.g. lupus). Patient has had major surgery or donated or lost 1 unit of blood in the last 4 weeks~* Patient has a history of drug or alcohol abuse in the last 2 years~* Patient has had a vaccine (with a live or attenuated virus) in the last two weeks

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Prednisone 15 mg (Type: EXPERIMENTAL): Prednisone 15 mg tablets once daily for 15 days
- Placebo 15 mg (Type: PLACEBO_COMPARATOR): Prednisone 15 mg placebo tablets once daily for 15 days
- Prednisone 7.5 mg (Type: EXPERIMENTAL): Prednisone 7.5 mg over-encapsulated tablets once daily for 15 days~As per adaptive dose-ranging design, this arm was added to the study because a difference between prednisone 15 mg and placebo was demonstrated during interim analysis.
- Placebo 7.5 mg (Type: PLACEBO_COMPARATOR): Prednisone 7.5 mg placebo over-encapsulated tablets once daily for 15 days~As per adaptive dose-ranging design, this arm was added to the study because a difference between prednisone 15 mg and placebo was demonstrated during interim analysis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study of RT-PEPC in Relapsed Mantle Cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed diagnosis of mantle cell Non-Hodgkin's Lymphoma with characteristic immunophenotypic profiles: CD5(+),CD23(-), CD19(+) or CD20(+), cyclin D1(+), and CD10(-)~* Patient has persistent / recurrent disease after standard chemotherapy~* Patient has not received either standard or investigational drugs within the last 3 weeks~* Available frozen tumor tissue obtained since completion of last prior therapy (rebiopsy if needed)~* Patient has measurable disease as defined by a tumor mass \> 1.5 cm in one dimension~* Age \> 18 years~* Absolute granulocyte count \> 1000 cells/mm3~* Platelet count \> 50,000 cells/mm3~* Creatinine \< 2.0 x ULN~* Total bilirubin \< 2.0 x ULN~* Patient has KPS \> 50%~* Patient agrees to use birth control if of reproductive potential~Exclusion Criteria:~* Known central nervous system (CNS) involvement by lymphoma~* Known HIV disease~* Known peripheral neuropathy \> grade 2~* Patient is pregnant or nursing~* Patient has had major surgery within the last 3 weeks~* Patient is receiving other investigational drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Study Treatment Arm (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Simple Approach to Prevent Hospitalization for COVID-19 Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male and female adult (≥18 years old)~* Subjects with early mild symptoms of COVID-19, who start the treatment without waiting results of a nasopharyngeal swab, if any~* Informed consent~Exclusion Criteria:~* Subjects of the two cohorts who require immediate hospital admission because of severe COVID-19 symptoms at onset according to family doctor's assessment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 'Recommended algorithm' cohort (Type: None): COVID-19 patients treated at home by their family doctors according to the proposed recommendations
- 'Historic control' cohort (Type: None): COVID-19 patients enrolled in the ORIGIN study of the Istituto di Ricerche Farmacologiche Mario Negri IRCCS and treated at home by family physicians with drug regimens that are not necessarily guided by those proposed in the recommendations

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete